Methods and compositions for treating a plaque-forming disease
First Claim
1. A method of treating a neurological disease or disorder of the central nervous system (CNS), comprising:
- displaying a therapeutic molecule capable of treating the neurological disease or disorder of the CNS on a viral display vehicle; and
introducing the viral display vehicle into a subject in need thereof by applying an effective amount of the viral display vehicle displaying the therapeutic molecule to an olfactory system of the subject to treat the neurological disease or disorder.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization. The methods of the present invention also generally relates to treating and/or diagnosing neurological diseases and disorders of the central nervous, regardless of whether the disease or disorder is plaque-forming or non-plaque forming.
-
Citations
39 Claims
-
1. A method of treating a neurological disease or disorder of the central nervous system (CNS), comprising:
-
displaying a therapeutic molecule capable of treating the neurological disease or disorder of the CNS on a viral display vehicle; and
introducing the viral display vehicle into a subject in need thereof by applying an effective amount of the viral display vehicle displaying the therapeutic molecule to an olfactory system of the subject to treat the neurological disease or disorder. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
- 15. A pharmaceutical composition for treating a neurological disease or disorder of the central nervous system (CNS), comprising a pharmaceutically acceptable carrier and an effective amount of a viral display vehicle displaying a therapeutic molecule and being capable of treating a neurological disease or disorder of the CNS.
-
17. A method of diagnosing the presence or extent of a neurological disease or disorder of the central nervous system (CNS) by in vivo imaging, comprising:
-
displaying on a viral display vehicle a diagnostic agent capable of being detected by in vivo imaging;
introducing the viral display vehicle into a subject by applying the viral display vehicle displaying the diagnostic agent to an olfactory system of the subject; and
detecting the displayed diagnostic agent in the subject by in vivo imaging to diagnose the presence or extent of the neurological disease or disorder. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
- 30. A pharmaceutical composition for diagnosing the presence or extent of a neurological disease or disorder of the central nervous system, comprising a pharmaceutically acceptable carrier and an effective amount of a viral display vehicle which displays a diagnostic agent capable of being detected by in vivo imaging.
-
33. A method for delivering a molecule to the central nervous system (CNS), comprising:
-
displaying the molecule on a viral display vehicle; and
introducing the viral display vehicle into a subject by applying the viral display vehicle displaying said molecule to an olfactory system of the subject. - View Dependent Claims (34, 35, 36)
-
-
37. A method for treating a plaque-forming disease, comprising introducing into the body of a recipient a display vehicle displaying a polypeptide representing at least one epitope of an aggregating protein associated with plaque formation in a plaque-forming disease to treat the plaque-forming disease, wherein the display vehicle is a papillomavirus-like particle and the at least one epitope is capable of eliciting antibodies capable of disaggregating the aggregating protein and/or inhibiting aggregation of the aggregating protein.
-
38. A method of preparing a papillomavirus-like particle display vehicle for treating a plaque-forming disease, comprising inserting into the nucleic acid encoding papillomavirus major capsid protein L1 a polynucleotide sequence encoding a polypeptide representing at least one epitope of an aggregating protein associated with plaque formation in the plaque-forming disease, wherein the at least one peptide is displayed by the papillomavirus-like particle display vehicle and is capable of eliciting antibodies capable of disaggregating the aggregating protein and/or inhibiting aggregation of the aggregating protein.
-
39. An immunizing composition, comprising a pharmaceutically acceptable carrier, diluent, excipient or auxiliary agent and an immunizing effective amount of a papillomavirus-like particle display vehicle displaying a polypeptide representing at least one epitope of an aggregating protein associated with plaque formation in a plaque-forming disease, wherein said at least one epitope is capable of eliciting antibodies capable of disaggregating the aggregating protein and/or inhibiting aggregation of the aggregating protein.
Specification